X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RenovoGem™ (gemcitabine), FDA-approved chemotherapy, delivered via the company’s proprietary delivery system, utilizes pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP®.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: RenovoRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
The collaboration aims to jointly discover and co-develop protein therapeutics for up to 5 oncology targets in advanced cancers, including small-cell and NSCLC. The agreement combines Generate:Biomedicines’ The Generate Platform with MD Anderson’s clinical research expertise.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Generate Biomedicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 27, 2023
Details:
TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T-lymphocyte product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogenic CryoTC technology.
Lead Product(s): Gamma Delta T-lymphocyte,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: OmnImmune
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: TC BioPharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2023
Details:
Under the agreement, Dr. Andreeff will evaluate the capacity of Eterna’s gene-edited induced pluripotent stem (iPS) cell therapeutic candidates to stimulate enhanced immune responses, including their effects on various aspects of T-cell mediated immunity.
Lead Product(s): iPSC-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Eterna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 01, 2022
Details:
VG201 is a first-in-class oncolytic HSV-1 virus that has enhanced oncolytic activity specifically for tumors expressing carcinoembryonic antigen (CEA) and is designed to produce immune-stimulating cytokines IL-12 and IL-15/IL15Rα.
Lead Product(s): VG201
Therapeutic Area: Oncology Product Name: VG201
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Virogin Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2022
Details:
The first patient dosed was diagnosed with non-small cell lung cancer with a KRAS G12D mutation, matching one of the ten TCRs within the Company’s TCR-T Cell Therapy.
Lead Product(s): TCR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Alaunos Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Results from the trial will compare RTA 744 (berubicin) to a current standard of care (Lomustine), with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine.
Lead Product(s): Berubicin Hydrochloride
Therapeutic Area: Oncology Product Name: RTA 744
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: CNS Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
The collaboration will build upon the HLA-G platform pioneered by Invectys to advance novel CAR T cell therapies including lead asset IVS-3001, through preclinical development with CTMC into early-phase clinical studies at MD Anderson.
Lead Product(s): HLA-G/CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: IVS-3001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Invectys
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 16, 2022
Details:
A single combination treatment with Dermacyte Liquid and Dermacyte Matrix (Human Amniotic Fluid) healed smaller of two wounds in four weeks. Dermacyte Liquid was injected under skin around wounds on patient’s thigh and lower leg.
Lead Product(s): Human Amniotic Fluid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Dermacyte Liquid
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Merakris Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
To define the incidence of dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of T-Cell Receptor T cells (herein referred to as TCR-T cell drug product administered without IL-2 (Arm A) or with IL-2 (Arm B).
Lead Product(s): TCR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Alaunos Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
